论文部分内容阅读
斯帕沙星(SPLX)是日本开发研制的新喹诺酮类合成抗菌剂,结构中含二个氟原子,格帕沙星(OPC-17116)是第四代氟喹诺酮类抗菌药,由于有独特的化学结构,与第三代氟喹诺酮类相比,有许多特点[1,2],洛美沙星(LMLX)亦属于二氟喹诺酮类抗菌药,由于结构的特点,使其药物动力学特性得到改善,保证体内代谢稳定和避免与其他药物联用时发生不良反应。1抗菌作用斯帕沙星与其他喹诺酮类相比,最大的改善是对葡萄球
Sparfloxacin (SPLX) is a new quinolone antibacterial agent developed and developed in Japan. It contains two fluorine atoms in its structure. Grepafloxacin (OPC-17116) is the fourth generation fluoroquinolone antibacterial agent. Due to its unique The chemical structure, compared with the third-generation fluoroquinolones, has many characteristics [1,2]. LMLX is also a difluoroquinolone antibacterial agent, which has its pharmacokinetic properties improved due to its structural characteristics , To ensure the stability of the body metabolism and avoid adverse reactions when combined with other drugs. 1 Antimicrobial Effect The biggest improvement over the sparfloxacin versus the other quinolones is on the grape ball